Stock TNGX TANGO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Real-time Estimate Cboe BZX
Other stock markets
 10:44:27 2024-05-30 am EDT 		5-day change 1st Jan Change
6.65 USD -1.48% Intraday chart for Tango Therapeutics, Inc. -6.27% -32.87%
May. 28 HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating MT
May. 24 Guggenheim Adjusts Tango Therapeutics Price Target to $14 From $16, Maintains Buy Rating MT

Evolution of the average Target Price on Tango Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b6ebd8d0e2dc428d01bf454a9532.W9NgB9q86PFkyxdKqaRIhvCaH2fcZPwHRykT1GpFIOY.EosNVY_TkbMRuH087-p44LjFZjWtBcpBNHZaoQl1ZrMX5Fd3jZGRxBOSRg~b7c09f2a6a2452763d00887cf8ec4f84

Analyst Recommendations on Tango Therapeutics, Inc.

HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating MT
Guggenheim Adjusts Tango Therapeutics Price Target to $14 From $16, Maintains Buy Rating MT
Barclays Adjusts Tango Therapeutics Price Target to $13 From $18, Maintains Overweight Rating MT
Wedbush Adjusts Tango Therapeutics Price Target to $11 From $18, Maintains Outperform Rating MT
Cantor Fitzgerald Initiates Coverage on Tango Therapeutics With Overweight Rating MT
H.C. Wainwright Adjusts Price Target on Tango Therapeutics to $17 From $16, Keeps Buy Rating MT
Piper Sandler Initiates Tango Therapeutics With Overweight Rating MT
B. Riley Starts Tango Therapeutics With Buy Rating, $16 Price Target MT
HC Wainwright Adjusts Tango Therapeutics Price Target to $16 From $11, Maintains Buy Rating MT
Wedbush Lowers Tango Therapeutics' Price Target to $18 From $21, Updates Model After Q4 Results; Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Tango Therapeutics to $11 From $10, Maintains Buy Rating MT
Wedbush Lifts Tango Therapeutics' Price Target to $21 From $20, Keeps Outperform Rating MT
HC Wainwright Starts Tango Therapeutics at Buy with $10 Price Target MT
Guggenheim Adjusts Tango Therapeutics' Price Target to $14 from $16, Keeps Buy Rating MT
TANGO THERAPEUTICS : SVB Leerink Initiates Coverage on Tango Therapeutics With Outperform Rating, $25 Price Target MT
TANGO THERAPEUTICS : Guggenheim Starts Tango Therapeutics at Buy with $16 Price Target MT
TANGO THERAPEUTICS : Barclays Initiates Tango Therapeutics With Overweight Rating, $18 Price Target MT
TANGO THERAPEUTICS : Wedbush Initiates Tango Therapeutics With Outperform Rating, $20 Price Target MT
TANGO THERAPEUTICS : Goldman Sachs Initiates Tango Therapeutics With Buy Rating, $17 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.75 USD
Average target price
14.86 USD
Spread / Average Target
+120.11%
High Price Target
19 USD
Spread / Highest target
+181.48%
Low Price Target
11 USD
Spread / Lowest Target
+62.96%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tango Therapeutics, Inc.

HC Wainwright
Barclays
Guggenheim
Wedbush
Cantor Fitzgerald
Piper Sandler
B. Riley
SVB Leerink
Goldman Sachs

Ratings for Tango Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TNGX Stock
  4. Consensus Tango Therapeutics, Inc.